原发性肝癌免疫检查点抑制剂治疗的进展与挑战  

Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma

作　　者：石琳娜(综述) 隋红(审校)[1] SHI Linna;SUI Hong(Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,哈尔滨150081

出　　处：《实用肿瘤学杂志》2020年第6期560-564,共5页Practical Oncology Journal

摘　　要：原发性肝细胞癌常常起病隐匿,病情进展迅速,疾病发现时常常已经丧失手术机会,全身治疗效果相对不理想。直到2015年肝癌免疫检查点抑制剂治疗相关临床研究陆续公布结果,为肝癌治疗开辟了新的方法,Nivolumab及Pembrolizumab相继获批用于肝癌二线治疗,免疫联合治疗在各临床研究中也取得较好的效果,但在免疫治疗过程中也出现超进展、免疫耐受等棘手问题,本文从免疫检查点抑制剂种类及免疫联合治疗等角度介绍了原发性肝细胞癌免疫治疗的最新进展,并讨论了原发性肝细胞癌免疫疗法在免疫治疗的超进展、冷热肿瘤转换以及效果预测等方面的潜在挑战。Primary hepatocellular carcinoma often starts and hides,the disease progresses rapidly,the chance of surgery is often lost when the disease is discovered,and the effect of systemic treatment is relatively unsatisfactory.Until 2015,the results of clinical studies related to the treatment of liver cancer immune checkpoint inhibitors were successively published,which opened up new methods for the treatment of liver cancer.Nivolumab and pembrolizumab have been approved for second-line treatment of liver cancer,and immunocombination therapy has also achieved good results in various clinical studies.However,in the process of immunotherapy,there are also difficult problems of hyperprogression and immune tolerance etc.This article introduces the latest progress of immunotherapy for primary hepatocellular carcinoma from the perspective of the types of immune checkpoint inhibitors and combined immunotherapy,and discusses the potential challenges of the primary hepatocellular carcinoma immunotherapy in the field of ultra-advanced immunotherapy,cold and hot tumor conversion,and efficacy prediction.

关 键 词：原发性肝癌 免疫检查点抑制剂 免疫联合治疗 

分 类 号：R735.7[医药卫生—肿瘤]